Compared with normal samples, RUNX1 was upregulated in a variety of tumors, including bladder cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, oral cancer, ovary cancer, pancreatic cancer, testis cancer, and thyroid cancer (all P < 0.05). Here, RUNX1 is linked to testicular cancer.